Related Experiment Video

Updated: Sep 28, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Benzimidazoles Against Certain Breast Cancer Drug Targets: A Review

Mehmet Murat Kisla1, Zeynep Ates-Alagoz1

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.

Mini Reviews in Medicinal Chemistry
|March 29, 2022
PubMed
Abstract

Insights

Benzimidazole derivatives show promise as anticancer agents for breast cancer (BC). This review highlights their potential by examining their action against specific BC molecular targets and pathways.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Drug Discovery

Background:

  • Benzimidazoles are established scaffolds in cancer therapy, particularly for breast cancer (BC).
  • Developing targeted anticancer agents requires understanding specific BC molecular targets.
  • The benzimidazole scaffold's ability to mimic biomolecules is key to its anticancer potential.

Purpose of the Study:

  • To review compounds targeting breast cancer (BC) biomolecular targets.
  • To present current research on innovative studies related to BC targets.

Main Methods:

  • Literature review of benzimidazole derivatives and their mechanisms of action.
  • Analysis of studies focusing on specific breast cancer (BC) pathways and enzymes.
  • Target-based collection and evaluation of benzimidazole derivatives.

Main Results:

  • Benzimidazole derivatives exhibit potential against various cancer types, including breast cancer (BC).
  • The benzimidazole moiety is implicated in numerous BC-related pathways and enzymes.
  • Structurally, benzimidazoles can mimic endogenous biomolecules, enhancing their therapeutic utility.

Conclusions:

  • Benzimidazole derivatives are valuable building blocks for developing novel breast cancer (BC) therapeutics.
  • Target-based strategies utilizing benzimidazoles show significant promise for BC treatment.
  • Further research into benzimidazole derivatives is warranted for effective breast cancer (BC) drug development.
Keywords:
Anticancer drugsbenzimidazolesbreast cancerpathwaysplethora of pathwaystarget-based biomolecules

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

512

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.7K